MetaVia says Phase 1 trial shows DA-1726 cuts mean body weight up to 9.1% at 48 mg dose

MetaVia Inc.

MTVA

0.00

MetaVia presented higher-dose Phase 1 results for obesity drug candidate DA-1726 at EASL 2026 on May 27.
The study showed meaningful, continuing weight loss with no sign of an early plateau during follow-up.
Safety profile looked manageable, with mostly mild-to-moderate gastrointestinal side effects and no treatment-related dropouts reported.
Exploratory liver scans suggested early improvements consistent with potential use in obesity-related liver disease, including MASH.
Ongoing Phase 1 titration studies are testing longer treatment and higher-dose strategies to support next-stage development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Metavia Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605270831PR_NEWS_USPR_____NY67791) on May 27, 2026, and is solely responsible for the information contained therein.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.